Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 1-Year Low – Time to Sell?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $35.53 and last traded at $36.21, with a volume of 958437 shares trading hands. The stock had previously closed at $37.82.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Piper Sandler dropped their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Canaccord Genuity Group upped their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $92.79.

Ultragenyx Pharmaceutical Stock Down 4.3 %

The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -5.71 and a beta of 0.67. The company’s fifty day moving average is $41.56 and its two-hundred day moving average is $46.62.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emil D. Kakkis sold 25,000 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $42.48, for a total value of $1,062,000.00. Following the sale, the chief executive officer now directly owns 2,158,985 shares in the company, valued at $91,713,682.80. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,643 shares of company stock worth $5,256,268. 5.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of the business. Bamco Inc. NY acquired a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $2,666,000. Principal Financial Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after purchasing an additional 76,150 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth $1,773,000. Wealth Enhancement Advisory Services LLC boosted its holdings in Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 294 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd grew its position in Ultragenyx Pharmaceutical by 193.1% in the third quarter. Y Intercept Hong Kong Ltd now owns 19,151 shares of the biopharmaceutical company’s stock valued at $1,064,000 after purchasing an additional 12,617 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.